ATR · NYSE · STOCK
AptarGroup (ATR) Stock Analysis
$127.40
52W $103.23 – $146.91
71/100
$8.19B
22.9
0.38
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is ATR Bullish or Bearish?
Bullish.
Innellis AI committee rates AptarGroup (ATR) Buy with a composite score of 71/100
, based on 5 analysts with 80% agreement.
Last updated September 05, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +4.25 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -15.75 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- News sentiment is positive (+1.00 across 1 articles, 14d) — News
Bear Case
- RSI at 20 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading below the lower Bollinger Band -- stretched to the downside — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 05, 2026
Overall Committee Score
71/100
Agreement
80%
Analysts
5
Conviction
Contested
Sector Rank
Top 1%
of 192 Healthcare peers
Growth Analyst
bullish
82
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
46
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− RSI at 20 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
bullish
70
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
90
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+1.00 across 1 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3059.07)
Investment Thesis Evolution
Committee score strengthened from 64.2 to 70.8.
- Committee agreement increased sharply from 50% to 80%.
- Bearish pressure eased: 1 signal(s) disappeared.
- Analyst(s) changed stance: Growth Analyst.
- Analyst(s) abstained: Value Analyst.
Analyst-level changes:
- Growth Analyst: stance neutral->bullish; score 56->82 (+26).
- Value Analyst abstained (was neutral at 58).
Comparing 2026-09-04 to 2026-09-05 (1 day apart).
Technical Analysis
RSI (14)
20.4
Oversold
MACD Histogram
-0.777
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Hh Hl
Support
$126.78
Resistance
$128.51
Bollinger %B
-0.13
Below Lower Band
Price vs Moving Averages
EMA 9
$131.54
Below
EMA 21
$132.30
Below
EMA 50
$130.54
Below
EMA 200
$129.22
Below
Fundamental Analysis
Valuation
81
Growth
73
Profitability
54
Financial Health
83
Cash Flow
70
Valuation
P/E Ratio
22.9×
P/B Ratio
3.12×
PEG Ratio
-4.37
Dividend Yield
1.50%
52W High
$146.91
52W Low
$103.23
Quality & Growth
ROE
1472.2%
ROA
747.8%
Gross Margin
2826.1%
Operating Margin
1237.0%
Revenue Growth YoY
—
Debt / Equity
0.54
AI Fundamental Assessment
P/E ratio of 22.9 (inexpensive relative to a 15-40x range); Price-to-book of 3.1x; PEG ratio of -4.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 14.7%; Return on assets of 7.5%; Net margin of 9.2%; Gross margin of 28.3%; Current ratio of 1.61 (healthy short-term liquidity); Debt-to-equity of 0.54; Free cash flow per share is positive (4.86); Most recent quarter beat estimates by 3.8%; 5 consecutive earnings beats; EPS growth accelerating (-4.8% -> +19.3% QoQ); Average YoY EPS growth of -14.5%; Analyst estimates rising over recent quarters
Get the Full ATR Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →